![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis |
Hyuk Yoon |
Intest Res. 2019;17(3):283-284. Published online July 25, 2019 DOI: https://doi.org/10.5217/ir.2019.00070 |
Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients Severe ulcerative colitis Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab Su1827 - Markers of Systemic Inflammation in Moderate-Severe Ulcerative Colitis: What Level of C-Reactive Protein Constitutes Acute Severe Ulcerative Colitis? Cost-Utility Analysis of Adalimumab for The Treatment of Moderate-To-Severe Ulcerative Colitis In Patients In Spain Mo1325 Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis |